Peter Kabos
Concepts (415)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Breast Neoplasms | 56 | 2025 | 2274 | 5.920 |
Why?
| | Receptors, Estrogen | 23 | 2025 | 435 | 3.090 |
Why?
| | Receptor, ErbB-2 | 17 | 2025 | 342 | 2.220 |
Why?
| | Estrogen Receptor alpha | 6 | 2025 | 144 | 1.560 |
Why?
| | Receptors, Progesterone | 12 | 2025 | 349 | 1.270 |
Why?
| | Brain Neoplasms | 15 | 2025 | 1267 | 1.050 |
Why?
| | Estradiol | 4 | 2025 | 525 | 1.050 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 12 | 2025 | 1702 | 0.880 |
Why?
| | Keratin-5 | 6 | 2022 | 49 | 0.820 |
Why?
| | Triple Negative Breast Neoplasms | 6 | 2023 | 203 | 0.790 |
Why?
| | Estrogens | 7 | 2023 | 369 | 0.780 |
Why?
| | Breast Neoplasms, Male | 3 | 2018 | 29 | 0.760 |
Why?
| | Biomarkers, Tumor | 7 | 2022 | 1235 | 0.750 |
Why?
| | Stem Cells | 8 | 2006 | 598 | 0.740 |
Why?
| | Antineoplastic Agents, Hormonal | 7 | 2025 | 165 | 0.690 |
Why?
| | Chromatin | 1 | 2025 | 517 | 0.690 |
Why?
| | Tetrahydronaphthalenes | 1 | 2021 | 30 | 0.690 |
Why?
| | MCF-7 Cells | 5 | 2025 | 123 | 0.670 |
Why?
| | Neoplasm Metastasis | 4 | 2020 | 664 | 0.660 |
Why?
| | Drug Resistance, Neoplasm | 5 | 2025 | 796 | 0.660 |
Why?
| | Immunoprecipitation | 4 | 2020 | 152 | 0.660 |
Why?
| | Neoplastic Cells, Circulating | 1 | 2020 | 79 | 0.640 |
Why?
| | Brain Edema | 2 | 2023 | 64 | 0.630 |
Why?
| | Benzodiazepines | 1 | 2021 | 155 | 0.630 |
Why?
| | Neurons | 8 | 2004 | 1593 | 0.610 |
Why?
| | Radiosurgery | 3 | 2023 | 390 | 0.590 |
Why?
| | Carcinoma, Intraductal, Noninfiltrating | 2 | 2017 | 58 | 0.590 |
Why?
| | Artifacts | 2 | 2016 | 129 | 0.580 |
Why?
| | Epithelial-Mesenchymal Transition | 1 | 2020 | 211 | 0.580 |
Why?
| | Leukocytes, Mononuclear | 2 | 2020 | 568 | 0.570 |
Why?
| | Binding Sites | 2 | 2025 | 1317 | 0.570 |
Why?
| | Female | 58 | 2025 | 73648 | 0.560 |
Why?
| | Gene Expression Regulation, Neoplastic | 11 | 2025 | 1388 | 0.550 |
Why?
| | Gene Expression Profiling | 7 | 2020 | 1755 | 0.540 |
Why?
| | Protein Kinase Inhibitors | 7 | 2025 | 905 | 0.540 |
Why?
| | Fanconi Anemia Complementation Group N Protein | 1 | 2017 | 5 | 0.530 |
Why?
| | Polyadenylation | 1 | 2017 | 42 | 0.530 |
Why?
| | Organoplatinum Compounds | 1 | 2016 | 46 | 0.520 |
Why?
| | Neoplastic Stem Cells | 7 | 2020 | 399 | 0.520 |
Why?
| | Carcinogenesis | 2 | 2020 | 216 | 0.520 |
Why?
| | High-Throughput Nucleotide Sequencing | 4 | 2019 | 541 | 0.520 |
Why?
| | Cancer-Associated Fibroblasts | 1 | 2016 | 19 | 0.510 |
Why?
| | Fluorouracil | 1 | 2016 | 201 | 0.480 |
Why?
| | CD146 Antigen | 3 | 2021 | 42 | 0.470 |
Why?
| | Pyridines | 5 | 2025 | 498 | 0.470 |
Why?
| | Mitochondrial Proteins | 1 | 2017 | 258 | 0.460 |
Why?
| | Piperazines | 4 | 2025 | 345 | 0.460 |
Why?
| | Microscopy, Electron, Scanning Transmission | 1 | 2014 | 4 | 0.460 |
Why?
| | Humans | 71 | 2025 | 138102 | 0.450 |
Why?
| | Thrombocytopenia | 1 | 2016 | 198 | 0.450 |
Why?
| | Maytansine | 1 | 2014 | 17 | 0.440 |
Why?
| | Microwaves | 1 | 2014 | 37 | 0.440 |
Why?
| | Cell Line, Tumor | 15 | 2025 | 3404 | 0.420 |
Why?
| | Microscopy | 1 | 2014 | 155 | 0.400 |
Why?
| | Trastuzumab | 5 | 2023 | 96 | 0.400 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2014 | 206 | 0.380 |
Why?
| | Analgesics, Opioid | 1 | 2021 | 1049 | 0.380 |
Why?
| | Neoplasms, Hormone-Dependent | 1 | 2012 | 38 | 0.380 |
Why?
| | Tumor Microenvironment | 4 | 2021 | 668 | 0.380 |
Why?
| | RNA-Binding Proteins | 1 | 2016 | 427 | 0.380 |
Why?
| | Tamoxifen | 5 | 2025 | 201 | 0.370 |
Why?
| | Antineoplastic Agents | 4 | 2023 | 2125 | 0.370 |
Why?
| | Homeodomain Proteins | 5 | 2018 | 506 | 0.370 |
Why?
| | MicroRNAs | 5 | 2016 | 678 | 0.360 |
Why?
| | Chemotherapy, Adjuvant | 5 | 2023 | 373 | 0.350 |
Why?
| | RNA | 2 | 2016 | 926 | 0.340 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2021 | 1052 | 0.340 |
Why?
| | Neoadjuvant Therapy | 3 | 2021 | 407 | 0.340 |
Why?
| | Image Processing, Computer-Assisted | 1 | 2014 | 748 | 0.330 |
Why?
| | Mutation | 3 | 2021 | 3994 | 0.330 |
Why?
| | Progestins | 5 | 2020 | 80 | 0.320 |
Why?
| | Antibodies, Monoclonal, Humanized | 2 | 2021 | 815 | 0.320 |
Why?
| | Pyrimidines | 3 | 2018 | 467 | 0.310 |
Why?
| | Tumor Cells, Cultured | 7 | 2020 | 946 | 0.300 |
Why?
| | Liver Neoplasms | 1 | 2015 | 759 | 0.300 |
Why?
| | Middle Aged | 19 | 2025 | 33509 | 0.300 |
Why?
| | Carcinoma, Ductal, Breast | 2 | 2020 | 83 | 0.290 |
Why?
| | Colorectal Neoplasms | 1 | 2016 | 817 | 0.290 |
Why?
| | Prognosis | 7 | 2021 | 3982 | 0.290 |
Why?
| | Hydrocephalus | 3 | 2023 | 110 | 0.290 |
Why?
| | Adenocarcinoma | 1 | 2015 | 880 | 0.290 |
Why?
| | Bone Marrow Cells | 2 | 2014 | 323 | 0.270 |
Why?
| | Signal Transduction | 5 | 2018 | 5068 | 0.270 |
Why?
| | Aged | 17 | 2025 | 23995 | 0.260 |
Why?
| | Astrocytes | 5 | 2023 | 211 | 0.250 |
Why?
| | Neoplasm Staging | 4 | 2021 | 1371 | 0.250 |
Why?
| | Helix-Loop-Helix Motifs | 2 | 2002 | 12 | 0.250 |
Why?
| | Aged, 80 and over | 7 | 2025 | 7638 | 0.250 |
Why?
| | Necrosis | 2 | 2019 | 247 | 0.240 |
Why?
| | Adult | 19 | 2025 | 38063 | 0.240 |
Why?
| | Cluster Analysis | 4 | 2019 | 515 | 0.240 |
Why?
| | Chondroitin Sulfate Proteoglycans | 2 | 2006 | 10 | 0.240 |
Why?
| | Fatty Acid Synthase, Type I | 1 | 2025 | 11 | 0.230 |
Why?
| | STAT1 Transcription Factor | 1 | 2025 | 71 | 0.230 |
Why?
| | Protein Binding | 2 | 2025 | 2232 | 0.230 |
Why?
| | Sequence Analysis, RNA | 2 | 2019 | 452 | 0.230 |
Why?
| | Neuroglia | 2 | 2003 | 171 | 0.230 |
Why?
| | Neoplasm Grading | 2 | 2017 | 306 | 0.220 |
Why?
| | Mice, Inbred NOD | 5 | 2021 | 597 | 0.220 |
Why?
| | Genetic Therapy | 2 | 2003 | 310 | 0.220 |
Why?
| | Aminopyridines | 2 | 2025 | 97 | 0.220 |
Why?
| | Disease-Free Survival | 4 | 2024 | 669 | 0.220 |
Why?
| | Aromatase Inhibitors | 2 | 2021 | 58 | 0.210 |
Why?
| | Carbolines | 1 | 2024 | 32 | 0.210 |
Why?
| | Triazines | 1 | 2024 | 43 | 0.210 |
Why?
| | Benzimidazoles | 2 | 2025 | 175 | 0.210 |
Why?
| | Progesterone | 3 | 2014 | 256 | 0.210 |
Why?
| | Morpholines | 1 | 2024 | 122 | 0.200 |
Why?
| | Animals | 27 | 2021 | 37151 | 0.200 |
Why?
| | Promoter Regions, Genetic | 3 | 2025 | 1237 | 0.200 |
Why?
| | Extracellular Matrix Proteins | 1 | 2004 | 155 | 0.200 |
Why?
| | Keratin-17 | 1 | 2022 | 4 | 0.200 |
Why?
| | Aquaporin 4 | 2 | 2023 | 96 | 0.190 |
Why?
| | Mice | 19 | 2021 | 17769 | 0.190 |
Why?
| | Nerve Regeneration | 1 | 2002 | 58 | 0.190 |
Why?
| | Triglycerides | 1 | 2025 | 528 | 0.190 |
Why?
| | Stromal Cells | 2 | 2020 | 111 | 0.190 |
Why?
| | Glioma | 5 | 2006 | 402 | 0.190 |
Why?
| | Class I Phosphatidylinositol 3-Kinases | 2 | 2025 | 97 | 0.190 |
Why?
| | Tumor Suppressor Proteins | 2 | 2015 | 324 | 0.190 |
Why?
| | Mice, SCID | 4 | 2020 | 368 | 0.190 |
Why?
| | Down-Regulation | 4 | 2015 | 635 | 0.190 |
Why?
| | Immunoconjugates | 1 | 2023 | 121 | 0.190 |
Why?
| | Cell-Free Nucleic Acids | 1 | 2022 | 38 | 0.180 |
Why?
| | Interleukin-13 Receptor alpha2 Subunit | 1 | 2021 | 6 | 0.180 |
Why?
| | Neoplasm Invasiveness | 3 | 2020 | 498 | 0.180 |
Why?
| | Cyclins | 1 | 2002 | 92 | 0.180 |
Why?
| | Medicare | 3 | 2023 | 786 | 0.180 |
Why?
| | Lipid Metabolism | 1 | 2025 | 523 | 0.180 |
Why?
| | Tumor Suppressor Protein p53 | 2 | 2015 | 524 | 0.180 |
Why?
| | Gene Regulatory Networks | 2 | 2014 | 310 | 0.170 |
Why?
| | Insulin Receptor Substrate Proteins | 1 | 2020 | 60 | 0.170 |
Why?
| | Cell Adhesion Molecules | 1 | 2021 | 177 | 0.170 |
Why?
| | Retrospective Studies | 6 | 2025 | 15750 | 0.170 |
Why?
| | RNA, Messenger | 3 | 2019 | 2799 | 0.160 |
Why?
| | Cancer Care Facilities | 1 | 2020 | 43 | 0.160 |
Why?
| | gamma-Aminobutyric Acid | 1 | 2002 | 194 | 0.160 |
Why?
| | Meningeal Carcinomatosis | 1 | 2020 | 8 | 0.160 |
Why?
| | Hyaluronan Receptors | 4 | 2014 | 103 | 0.160 |
Why?
| | Carcinoma, Lobular | 1 | 2020 | 49 | 0.160 |
Why?
| | Antineoplastic Agents, Immunological | 2 | 2019 | 190 | 0.160 |
Why?
| | Cell Proliferation | 6 | 2025 | 2472 | 0.160 |
Why?
| | SEER Program | 1 | 2021 | 229 | 0.160 |
Why?
| | Gene Library | 2 | 2019 | 119 | 0.160 |
Why?
| | Transcriptome | 2 | 2019 | 969 | 0.160 |
Why?
| | Collagen | 2 | 2020 | 454 | 0.150 |
Why?
| | Repressor Proteins | 1 | 2002 | 423 | 0.150 |
Why?
| | Treatment Outcome | 6 | 2025 | 10832 | 0.150 |
Why?
| | Lymphatic Metastasis | 2 | 2017 | 322 | 0.150 |
Why?
| | Antigens, Neoplasm | 1 | 2021 | 317 | 0.150 |
Why?
| | ErbB Receptors | 2 | 2020 | 609 | 0.150 |
Why?
| | Paclitaxel | 1 | 2020 | 237 | 0.150 |
Why?
| | Receptor, Fibroblast Growth Factor, Type 1 | 1 | 2018 | 53 | 0.140 |
Why?
| | beta Catenin | 1 | 2020 | 252 | 0.140 |
Why?
| | Xenograft Model Antitumor Assays | 4 | 2017 | 865 | 0.140 |
Why?
| | Heterografts | 4 | 2020 | 135 | 0.130 |
Why?
| | RNA Polymerase III | 1 | 2017 | 28 | 0.130 |
Why?
| | Disease Progression | 4 | 2018 | 2730 | 0.130 |
Why?
| | 3' Untranslated Regions | 1 | 2017 | 145 | 0.130 |
Why?
| | Quinolines | 3 | 2025 | 154 | 0.130 |
Why?
| | Pyrroles | 1 | 2017 | 212 | 0.130 |
Why?
| | Neoplasms, Radiation-Induced | 1 | 2016 | 92 | 0.120 |
Why?
| | Receptors, Androgen | 1 | 2017 | 149 | 0.120 |
Why?
| | Genital Neoplasms, Female | 1 | 2017 | 94 | 0.120 |
Why?
| | Single-Cell Analysis | 1 | 2019 | 324 | 0.120 |
Why?
| | Gene Expression | 2 | 2016 | 1487 | 0.120 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2016 | 979 | 0.120 |
Why?
| | Ovary | 1 | 2017 | 223 | 0.120 |
Why?
| | Neoplasms, Second Primary | 1 | 2016 | 114 | 0.120 |
Why?
| | Combined Modality Therapy | 2 | 2019 | 1234 | 0.120 |
Why?
| | Ribosomal Proteins | 1 | 2015 | 92 | 0.120 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 442 | 0.120 |
Why?
| | Paracrine Communication | 1 | 2015 | 66 | 0.120 |
Why?
| | DNA Primers | 1 | 2016 | 508 | 0.110 |
Why?
| | Isoquinolines | 2 | 2025 | 43 | 0.110 |
Why?
| | Pyrazoles | 1 | 2018 | 421 | 0.110 |
Why?
| | Hodgkin Disease | 1 | 2016 | 138 | 0.110 |
Why?
| | Risk Reduction Behavior | 1 | 2016 | 217 | 0.110 |
Why?
| | Azetidines | 2 | 2025 | 43 | 0.110 |
Why?
| | Fibroblasts | 1 | 2020 | 1002 | 0.110 |
Why?
| | Azepines | 1 | 2015 | 97 | 0.110 |
Why?
| | Reactive Oxygen Species | 1 | 2017 | 626 | 0.110 |
Why?
| | STAT5 Transcription Factor | 1 | 2014 | 57 | 0.110 |
Why?
| | Obesity | 2 | 2018 | 3037 | 0.110 |
Why?
| | Receptors, Steroid | 1 | 2014 | 46 | 0.110 |
Why?
| | Odds Ratio | 1 | 2017 | 1077 | 0.110 |
Why?
| | Microscopy, Atomic Force | 1 | 2014 | 126 | 0.110 |
Why?
| | Peptides | 1 | 2020 | 980 | 0.110 |
Why?
| | Clinical Decision-Making | 1 | 2017 | 329 | 0.110 |
Why?
| | Software | 2 | 2019 | 665 | 0.100 |
Why?
| | Apoptosis | 4 | 2017 | 2555 | 0.100 |
Why?
| | Opioid-Related Disorders | 1 | 2021 | 533 | 0.100 |
Why?
| | CD24 Antigen | 1 | 2012 | 20 | 0.100 |
Why?
| | DNA-Binding Proteins | 2 | 2015 | 1477 | 0.100 |
Why?
| | Sensitivity and Specificity | 2 | 2016 | 1946 | 0.100 |
Why?
| | Disease Models, Animal | 4 | 2017 | 4309 | 0.100 |
Why?
| | Anthracyclines | 2 | 2023 | 42 | 0.100 |
Why?
| | Retinoids | 1 | 2012 | 34 | 0.100 |
Why?
| | RNA Interference | 1 | 2014 | 468 | 0.090 |
Why?
| | Cell Differentiation | 4 | 2004 | 1999 | 0.090 |
Why?
| | Clinical Trials as Topic | 1 | 2017 | 1032 | 0.090 |
Why?
| | Taxoids | 2 | 2023 | 101 | 0.090 |
Why?
| | Comorbidity | 1 | 2017 | 1638 | 0.090 |
Why?
| | Doxorubicin | 3 | 2022 | 338 | 0.090 |
Why?
| | Small Molecule Libraries | 1 | 2012 | 94 | 0.090 |
Why?
| | Extracellular Signal-Regulated MAP Kinases | 1 | 2012 | 174 | 0.090 |
Why?
| | Male | 8 | 2018 | 67984 | 0.090 |
Why?
| | Genome, Human | 1 | 2014 | 419 | 0.090 |
Why?
| | United States | 4 | 2023 | 15028 | 0.090 |
Why?
| | Drug Discovery | 1 | 2012 | 146 | 0.090 |
Why?
| | Tumor Burden | 1 | 2012 | 306 | 0.090 |
Why?
| | Rats | 5 | 2017 | 5564 | 0.090 |
Why?
| | Mitochondria | 1 | 2017 | 951 | 0.090 |
Why?
| | Logistic Models | 1 | 2016 | 2081 | 0.080 |
Why?
| | Feasibility Studies | 1 | 2014 | 971 | 0.080 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 2 | 2002 | 243 | 0.080 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2012 | 758 | 0.080 |
Why?
| | Dendritic Cells | 2 | 2004 | 491 | 0.080 |
Why?
| | Estrogen Antagonists | 1 | 2010 | 45 | 0.080 |
Why?
| | Nuclear Proteins | 1 | 2015 | 709 | 0.080 |
Why?
| | Time Factors | 3 | 2020 | 6845 | 0.080 |
Why?
| | Lung Neoplasms | 1 | 2023 | 2571 | 0.080 |
Why?
| | Transforming Growth Factor beta | 1 | 2012 | 487 | 0.080 |
Why?
| | Administration, Oral | 2 | 2024 | 786 | 0.080 |
Why?
| | BRCA2 Protein | 1 | 2009 | 63 | 0.080 |
Why?
| | Cell Culture Techniques | 2 | 2020 | 363 | 0.080 |
Why?
| | Pregnancy Complications, Neoplastic | 1 | 2009 | 55 | 0.080 |
Why?
| | Thrombophilia | 1 | 2009 | 83 | 0.070 |
Why?
| | Receptors, CXCR4 | 2 | 2006 | 87 | 0.070 |
Why?
| | Practice Patterns, Physicians' | 1 | 2017 | 1299 | 0.070 |
Why?
| | Brain | 2 | 2023 | 2725 | 0.070 |
Why?
| | Cell Movement | 3 | 2015 | 971 | 0.070 |
Why?
| | Cells, Cultured | 3 | 2006 | 4160 | 0.070 |
Why?
| | Stem Cell Transplantation | 3 | 2004 | 178 | 0.070 |
Why?
| | Tumor Necrosis Factor-alpha | 2 | 2002 | 1239 | 0.070 |
Why?
| | Proteoglycans | 2 | 2006 | 110 | 0.070 |
Why?
| | Genetic Predisposition to Disease | 1 | 2016 | 2374 | 0.070 |
Why?
| | Rats, Sprague-Dawley | 2 | 2002 | 2472 | 0.070 |
Why?
| | Radiotherapy, Adjuvant | 2 | 2018 | 214 | 0.070 |
Why?
| | Algorithms | 1 | 2014 | 1711 | 0.070 |
Why?
| | Immunohistochemistry | 2 | 2017 | 1718 | 0.060 |
Why?
| | Aurora Kinase A | 2 | 2018 | 57 | 0.060 |
Why?
| | Drug Delivery Systems | 1 | 2010 | 357 | 0.060 |
Why?
| | Risk Factors | 2 | 2020 | 10433 | 0.060 |
Why?
| | Severity of Illness Index | 1 | 2014 | 2838 | 0.060 |
Why?
| | Biopsy | 2 | 2020 | 1089 | 0.060 |
Why?
| | Nervous System | 1 | 2006 | 67 | 0.060 |
Why?
| | Rats, Inbred F344 | 2 | 2003 | 267 | 0.060 |
Why?
| | Cyclin-Dependent Kinase 4 | 1 | 2025 | 47 | 0.060 |
Why?
| | Cyclin-Dependent Kinase 6 | 1 | 2025 | 42 | 0.060 |
Why?
| | Oxazoles | 1 | 2025 | 37 | 0.060 |
Why?
| | Neoplasm Transplantation | 2 | 2016 | 250 | 0.060 |
Why?
| | Mass Spectrometry | 2 | 2020 | 739 | 0.060 |
Why?
| | Tomography, X-Ray Computed | 1 | 2015 | 2693 | 0.060 |
Why?
| | Infant, Premature, Diseases | 1 | 2006 | 103 | 0.060 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 5 | 1 | 2004 | 1 | 0.060 |
Why?
| | Aggrecans | 1 | 2004 | 15 | 0.060 |
Why?
| | Purines | 1 | 2025 | 177 | 0.050 |
Why?
| | Lectins, C-Type | 1 | 2004 | 65 | 0.050 |
Why?
| | Cyclophosphamide | 2 | 2018 | 241 | 0.050 |
Why?
| | Maximum Tolerated Dose | 1 | 2024 | 199 | 0.050 |
Why?
| | Quinazolines | 1 | 2025 | 249 | 0.050 |
Why?
| | Cell Line | 2 | 2014 | 2865 | 0.050 |
Why?
| | Hemangioma, Cavernous, Central Nervous System | 1 | 2003 | 8 | 0.050 |
Why?
| | Mastectomy, Segmental | 2 | 2017 | 96 | 0.050 |
Why?
| | Follow-Up Studies | 2 | 2025 | 5144 | 0.050 |
Why?
| | Adipose Tissue | 2 | 2018 | 645 | 0.050 |
Why?
| | Aromatase | 1 | 2023 | 32 | 0.050 |
Why?
| | Inhibitor of Differentiation Protein 2 | 1 | 2002 | 5 | 0.050 |
Why?
| | Inhibitor of Differentiation Protein 1 | 1 | 2002 | 8 | 0.050 |
Why?
| | Glioblastoma | 2 | 2006 | 341 | 0.050 |
Why?
| | Camptothecin | 1 | 2023 | 121 | 0.050 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2003 | 58 | 0.050 |
Why?
| | Edema | 1 | 2023 | 130 | 0.050 |
Why?
| | Mice, Inbred C57BL | 5 | 2004 | 5769 | 0.050 |
Why?
| | Hepatocyte Nuclear Factor 3-alpha | 1 | 2022 | 8 | 0.050 |
Why?
| | Neurites | 1 | 2002 | 48 | 0.050 |
Why?
| | Pyramidal Tracts | 1 | 2002 | 30 | 0.050 |
Why?
| | Sciatic Nerve | 1 | 2002 | 58 | 0.050 |
Why?
| | Gonadotropin-Releasing Hormone | 1 | 2024 | 212 | 0.050 |
Why?
| | Vimentin | 1 | 2022 | 52 | 0.050 |
Why?
| | Transcription Factor HES-1 | 1 | 2002 | 5 | 0.050 |
Why?
| | Interleukin-12 | 1 | 2002 | 123 | 0.050 |
Why?
| | Phenotype | 1 | 2010 | 3158 | 0.050 |
Why?
| | Frontal Lobe | 1 | 2002 | 154 | 0.040 |
Why?
| | Blotting, Western | 1 | 2004 | 1223 | 0.040 |
Why?
| | Oligonucleotides, Antisense | 1 | 2002 | 109 | 0.040 |
Why?
| | Fibroblast Growth Factors | 1 | 2002 | 177 | 0.040 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2002 | 121 | 0.040 |
Why?
| | Mice, Inbred BALB C | 1 | 2004 | 1260 | 0.040 |
Why?
| | Ependymoma | 1 | 2003 | 163 | 0.040 |
Why?
| | Protein-Lysine 6-Oxidase | 1 | 2020 | 14 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2024 | 414 | 0.040 |
Why?
| | Cerebral Cortex | 1 | 2004 | 434 | 0.040 |
Why?
| | Clinical Trials, Phase I as Topic | 1 | 2020 | 50 | 0.040 |
Why?
| | Nucleosomes | 1 | 2022 | 155 | 0.040 |
Why?
| | Hospitals, University | 1 | 2021 | 179 | 0.040 |
Why?
| | Neoplasms | 1 | 2015 | 2712 | 0.040 |
Why?
| | Nervous System Diseases | 1 | 2003 | 273 | 0.040 |
Why?
| | Animals, Newborn | 1 | 2002 | 847 | 0.040 |
Why?
| | Membrane Glycoproteins | 1 | 2002 | 501 | 0.040 |
Why?
| | Adherens Junctions | 1 | 2020 | 25 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2024 | 2022 | 0.040 |
Why?
| | Gene Knockout Techniques | 1 | 2020 | 118 | 0.040 |
Why?
| | Protein Interaction Mapping | 1 | 2020 | 106 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 878 | 0.040 |
Why?
| | Interferon-gamma | 1 | 2002 | 788 | 0.040 |
Why?
| | Mice, Nude | 2 | 2015 | 690 | 0.040 |
Why?
| | beta-Galactosidase | 3 | 2002 | 79 | 0.040 |
Why?
| | DNA, Complementary | 1 | 2019 | 275 | 0.040 |
Why?
| | Loss of Function Mutation | 1 | 2018 | 46 | 0.040 |
Why?
| | Maintenance Chemotherapy | 1 | 2018 | 36 | 0.040 |
Why?
| | Cadherins | 1 | 2020 | 201 | 0.040 |
Why?
| | Immunotherapy | 1 | 2003 | 631 | 0.040 |
Why?
| | Nausea | 1 | 2018 | 111 | 0.040 |
Why?
| | Wnt Signaling Pathway | 1 | 2020 | 196 | 0.030 |
Why?
| | Breast | 1 | 2018 | 157 | 0.030 |
Why?
| | Phenylthiohydantoin | 1 | 2017 | 42 | 0.030 |
Why?
| | Mastectomy | 1 | 2018 | 139 | 0.030 |
Why?
| | Diarrhea | 1 | 2018 | 184 | 0.030 |
Why?
| | Mammary Neoplasms, Experimental | 1 | 2017 | 68 | 0.030 |
Why?
| | Area Under Curve | 1 | 2017 | 306 | 0.030 |
Why?
| | Antigens, CD | 1 | 2020 | 530 | 0.030 |
Why?
| | Ovariectomy | 1 | 2017 | 155 | 0.030 |
Why?
| | Steroids | 1 | 2017 | 159 | 0.030 |
Why?
| | Benzamides | 1 | 2017 | 209 | 0.030 |
Why?
| | Nitriles | 1 | 2017 | 176 | 0.030 |
Why?
| | Cell Membrane | 1 | 2020 | 713 | 0.030 |
Why?
| | Fatigue | 1 | 2018 | 338 | 0.030 |
Why?
| | Apoptosis Regulatory Proteins | 2 | 2009 | 191 | 0.030 |
Why?
| | Flow Cytometry | 2 | 2012 | 1194 | 0.030 |
Why?
| | Proto-Oncogene Proteins c-mdm2 | 1 | 2015 | 66 | 0.030 |
Why?
| | Tumor Protein p73 | 1 | 2015 | 14 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 441 | 0.030 |
Why?
| | Postmenopause | 1 | 2017 | 370 | 0.030 |
Why?
| | Weight Gain | 1 | 2018 | 538 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2015 | 329 | 0.030 |
Why?
| | Molecular Targeted Therapy | 1 | 2017 | 407 | 0.030 |
Why?
| | Transcription Factors | 1 | 2002 | 1709 | 0.030 |
Why?
| | Serrate-Jagged Proteins | 1 | 2014 | 27 | 0.030 |
Why?
| | Jagged-1 Protein | 1 | 2014 | 23 | 0.030 |
Why?
| | Argonaute Proteins | 1 | 2014 | 27 | 0.030 |
Why?
| | Wnt-5a Protein | 1 | 2014 | 24 | 0.030 |
Why?
| | Matrix Metalloproteinase 2 | 1 | 2014 | 56 | 0.030 |
Why?
| | Testosterone | 1 | 2017 | 403 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2020 | 1455 | 0.030 |
Why?
| | Cellular Microenvironment | 1 | 2014 | 84 | 0.030 |
Why?
| | Cell Transformation, Neoplastic | 1 | 2015 | 329 | 0.030 |
Why?
| | Gene Expression Regulation | 1 | 2022 | 2586 | 0.020 |
Why?
| | Wnt Proteins | 1 | 2014 | 135 | 0.020 |
Why?
| | Interleukin-6 | 1 | 2017 | 786 | 0.020 |
Why?
| | Guideline Adherence | 1 | 2017 | 557 | 0.020 |
Why?
| | Acitretin | 1 | 2012 | 3 | 0.020 |
Why?
| | Miconazole | 1 | 2012 | 5 | 0.020 |
Why?
| | Calcium-Binding Proteins | 1 | 2014 | 214 | 0.020 |
Why?
| | Socioeconomic Factors | 1 | 2017 | 1312 | 0.020 |
Why?
| | Isotretinoin | 1 | 2012 | 24 | 0.020 |
Why?
| | Intercellular Signaling Peptides and Proteins | 1 | 2014 | 384 | 0.020 |
Why?
| | Luciferases | 1 | 2012 | 149 | 0.020 |
Why?
| | Genes, Reporter | 1 | 2012 | 272 | 0.020 |
Why?
| | Tretinoin | 1 | 2012 | 122 | 0.020 |
Why?
| | Biomarkers | 2 | 2017 | 4111 | 0.020 |
Why?
| | Vascular Endothelial Growth Factor A | 1 | 2014 | 552 | 0.020 |
Why?
| | Magnetic Resonance Imaging | 2 | 2019 | 3608 | 0.020 |
Why?
| | Risk Assessment | 1 | 2020 | 3471 | 0.020 |
Why?
| | Green Fluorescent Proteins | 1 | 2012 | 396 | 0.020 |
Why?
| | Proto-Oncogene Proteins | 1 | 2014 | 624 | 0.020 |
Why?
| | Diet | 1 | 2018 | 1290 | 0.020 |
Why?
| | Colorado | 1 | 2020 | 4553 | 0.020 |
Why?
| | Base Sequence | 1 | 2014 | 2180 | 0.020 |
Why?
| | HEK293 Cells | 1 | 2012 | 730 | 0.020 |
Why?
| | Age Factors | 1 | 2017 | 3285 | 0.020 |
Why?
| | Pregnancy Trimester, Second | 1 | 2009 | 80 | 0.020 |
Why?
| | Molecular Sequence Data | 1 | 2014 | 2925 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1557 | 0.020 |
Why?
| | Hypertension | 1 | 2018 | 1310 | 0.020 |
Why?
| | Pregnancy Trimester, First | 1 | 2009 | 137 | 0.020 |
Why?
| | Endothelial Cells | 1 | 2014 | 786 | 0.020 |
Why?
| | Lymph Node Excision | 1 | 2009 | 168 | 0.020 |
Why?
| | Transplantation, Heterologous | 1 | 2008 | 195 | 0.020 |
Why?
| | Membrane Proteins | 1 | 2014 | 1154 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 2008 | 174 | 0.020 |
Why?
| | CD8-Positive T-Lymphocytes | 2 | 2002 | 912 | 0.020 |
Why?
| | CD4-Positive T-Lymphocytes | 2 | 2002 | 1101 | 0.020 |
Why?
| | Chemokines, CXC | 1 | 2006 | 71 | 0.020 |
Why?
| | Nestin | 1 | 2006 | 19 | 0.020 |
Why?
| | Laminin | 1 | 2006 | 72 | 0.020 |
Why?
| | Intermediate Filament Proteins | 1 | 2006 | 57 | 0.020 |
Why?
| | Infant, Newborn | 2 | 2009 | 6140 | 0.020 |
Why?
| | Chemokine CXCL12 | 1 | 2006 | 83 | 0.020 |
Why?
| | Glial Fibrillary Acidic Protein | 1 | 2006 | 100 | 0.010 |
Why?
| | Lasers | 1 | 2006 | 130 | 0.010 |
Why?
| | Drug Combinations | 1 | 2006 | 341 | 0.010 |
Why?
| | Adolescent | 1 | 2024 | 21637 | 0.010 |
Why?
| | Culture Media, Conditioned | 1 | 2004 | 112 | 0.010 |
Why?
| | RNA, Small Interfering | 1 | 2006 | 621 | 0.010 |
Why?
| | Injections, Intralesional | 1 | 2003 | 35 | 0.010 |
Why?
| | TNF-Related Apoptosis-Inducing Ligand | 1 | 2002 | 49 | 0.010 |
Why?
| | 3T3 Cells | 1 | 2002 | 164 | 0.010 |
Why?
| | Random Allocation | 1 | 2003 | 362 | 0.010 |
Why?
| | Models, Neurological | 1 | 2004 | 245 | 0.010 |
Why?
| | Nerve Tissue Proteins | 1 | 2006 | 596 | 0.010 |
Why?
| | Adenoviridae | 1 | 2002 | 198 | 0.010 |
Why?
| | Infant, Premature | 1 | 2006 | 580 | 0.010 |
Why?
| | Reference Values | 1 | 2003 | 803 | 0.010 |
Why?
| | Genetic Vectors | 1 | 2002 | 335 | 0.010 |
Why?
| | Oligodendroglia | 1 | 2002 | 178 | 0.010 |
Why?
| | Transfection | 1 | 2002 | 938 | 0.010 |
Why?
| | Recombinant Fusion Proteins | 1 | 2002 | 662 | 0.010 |
Why?
| | Survival Rate | 1 | 2003 | 1912 | 0.010 |
Why?
| | Case-Control Studies | 1 | 2006 | 3569 | 0.010 |
Why?
| | Pregnancy | 1 | 2009 | 6789 | 0.010 |
Why?
| | Vaccination | 1 | 2003 | 1431 | 0.010 |
Why?
| | Prospective Studies | 1 | 2006 | 7603 | 0.010 |
Why?
| | Infant | 1 | 2006 | 9566 | 0.010 |
Why?
|
|
Kabos's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|